T Li1, Y Zhao1, X Yang1, Y Feng1, Y Li2, Y Wu2, M Zhang2, X Li1, H Hu1, J Zhang1, L Yuan1, Y Liu3, X Sun3, P Qin4, C Chen5, D Hu6. 1. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, Henan, People's Republic of China. 2. Department of Biostatistics and Epidemiology, School of Public Health, Shenzhen University Health Science Center, Shenzhen, Guangdong, People's Republic of China. 3. Department of General Practice, The Affiliated Luohu Hospital of Shenzhen University Health Science Center, Shenzhen, 518001, Guangdong, People's Republic of China. 4. Department of Endocrinology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, People's Republic of China. 5. Department of Medical Record Management, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, People's Republic of China. 6. Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, Henan, People's Republic of China. dongshenghu563@126.com.
Abstract
BACKGROUND: Insulin-like growth factor-1 (IGF-1) has increasingly been reported as linked to cardiovascular (CV) events; however, reported results have been inconsistent, and no meta-analysis has been undertaken to quantitatively assess this association. METHODS: We searched PubMed, Embase, and Web of Science databases for cohort articles published up to December 1, 2020. Fixed or random-effects models were used to estimate the summary relative risks (RRs) and 95% confidence intervals (CIs) of CV events in relation to IGF-1. Restricted cubic splines were used to model the dose-response association. RESULTS: We identified 11 articles (thirteen cohort studies) covering a total of 22,995 participants and 3040 CV events in this meta-analysis. The risk of overall CV events reduced by 16% from the highest to the lowest IGF-1 levels (RR 0.83, 95% CI 0.72-0.95), while the occurrence of CV events reduced by 28% (RR 0.72, 95% CI 0.56-0.92), but not for CV deaths, however (RR 1.00, 95% CI 0.65-1.55). We also found linear associations between IGF-1 levels and CV events. With each per 45 μg/mL IGF-1 increase, the pooled RRs were 0.91 (95% CI 0.86-0.96), 0.91 (95% CI 0.85-0.97) and 0.91 (95% CI 0.84-0.98) for overall CV events, for the occurrence of CV events, and for CV deaths, respectively. CONCLUSIONS: Our findings based on cohort studies support the contention that any increase in IGF-1 is helpful in reducing the overall risk of CV events. As an important biomarker for assessing the likelihood of CV events, IGF-1 appears to offer a promising prognostic approach for aiding prevention.
BACKGROUND: Insulin-like growth factor-1 (IGF-1) has increasingly been reported as linked to cardiovascular (CV) events; however, reported results have been inconsistent, and no meta-analysis has been undertaken to quantitatively assess this association. METHODS: We searched PubMed, Embase, and Web of Science databases for cohort articles published up to December 1, 2020. Fixed or random-effects models were used to estimate the summary relative risks (RRs) and 95% confidence intervals (CIs) of CV events in relation to IGF-1. Restricted cubic splines were used to model the dose-response association. RESULTS: We identified 11 articles (thirteen cohort studies) covering a total of 22,995 participants and 3040 CV events in this meta-analysis. The risk of overall CV events reduced by 16% from the highest to the lowest IGF-1 levels (RR 0.83, 95% CI 0.72-0.95), while the occurrence of CV events reduced by 28% (RR 0.72, 95% CI 0.56-0.92), but not for CV deaths, however (RR 1.00, 95% CI 0.65-1.55). We also found linear associations between IGF-1 levels and CV events. With each per 45 μg/mL IGF-1 increase, the pooled RRs were 0.91 (95% CI 0.86-0.96), 0.91 (95% CI 0.85-0.97) and 0.91 (95% CI 0.84-0.98) for overall CV events, for the occurrence of CV events, and for CV deaths, respectively. CONCLUSIONS: Our findings based on cohort studies support the contention that any increase in IGF-1 is helpful in reducing the overall risk of CV events. As an important biomarker for assessing the likelihood of CV events, IGF-1 appears to offer a promising prognostic approach for aiding prevention.
Authors: Sally L Ricketts; Katrijn L Rensing; Jeff M Holly; Li Chen; Elizabeth H Young; Robert Luben; Sofie Ashford; Kijoung Song; Xin Yuan; Abbas Dehghan; Benjamin J Wright; Dawn M Waterworth; Vincent Mooser; Gérard Waeber; Peter Vollenweider; Stephen E Epstein; Mary S Burnett; Joseph M Devaney; Hakon H Hakonarson; Daniel J Rader; Muredach P Reilly; John Danesh; Simon G Thompson; Alison M Dunning; Cornelia M van Duijn; Nilesh J Samani; Ruth McPherson; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu Journal: Int J Mol Epidemiol Genet Date: 2011-08-03
Authors: Christa C van Bunderen; I Caroline van Nieuwpoort; Natasja M van Schoor; Dorly J H Deeg; Paul Lips; Madeleine L Drent Journal: J Clin Endocrinol Metab Date: 2010-07-07 Impact factor: 5.958
Authors: Aletta E Schutte; Elena Conti; Catharina Mc Mels; Wayne Smith; Ruan Kruger; Shani Botha; Lucio Gnessi; Massimo Volpe; Hugo W Huisman Journal: Eur J Prev Cardiol Date: 2016-07-22 Impact factor: 7.804
Authors: Ramachandran S Vasan; Lisa M Sullivan; Ralph B D'Agostino; Ronenn Roubenoff; Tamara Harris; Douglas B Sawyer; Daniel Levy; Peter W F Wilson Journal: Ann Intern Med Date: 2003-10-21 Impact factor: 25.391
Authors: Gysèle S Bleumink; Ingrid Rietveld; Joop A M J L Janssen; Elisabeth F C van Rossum; Jaap W Deckers; Albert Hofman; Jacqueline C M Witteman; Cornelia M van Duijn; Bruno H Ch Stricker Journal: Am J Cardiol Date: 2004-08-01 Impact factor: 2.778
Authors: Jia Sun; Jonas Axelsson; Anna Machowska; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Karin Lindström; Peter Stenvinkel; Abdul Rashid Qureshi Journal: Clin J Am Soc Nephrol Date: 2016-06-08 Impact factor: 8.237
Authors: J M Hinojosa-Amaya; E V Varlamov; C G Yedinak; J S Cetas; S McCartney; S Banskota; M Fleseriu Journal: J Endocrinol Invest Date: 2021-04-24 Impact factor: 4.256
Authors: Gregory A Roth; George A Mensah; Catherine O Johnson; Giovanni Addolorato; Enrico Ammirati; Larry M Baddour; Noël C Barengo; Andrea Z Beaton; Emelia J Benjamin; Catherine P Benziger; Aimé Bonny; Michael Brauer; Marianne Brodmann; Thomas J Cahill; Jonathan Carapetis; Alberico L Catapano; Sumeet S Chugh; Leslie T Cooper; Josef Coresh; Michael Criqui; Nicole DeCleene; Kim A Eagle; Sophia Emmons-Bell; Valery L Feigin; Joaquim Fernández-Solà; Gerry Fowkes; Emmanuela Gakidou; Scott M Grundy; Feng J He; George Howard; Frank Hu; Lesley Inker; Ganesan Karthikeyan; Nicholas Kassebaum; Walter Koroshetz; Carl Lavie; Donald Lloyd-Jones; Hong S Lu; Antonio Mirijello; Awoke Misganaw Temesgen; Ali Mokdad; Andrew E Moran; Paul Muntner; Jagat Narula; Bruce Neal; Mpiko Ntsekhe; Glaucia Moraes de Oliveira; Catherine Otto; Mayowa Owolabi; Michael Pratt; Sanjay Rajagopalan; Marissa Reitsma; Antonio Luiz P Ribeiro; Nancy Rigotti; Anthony Rodgers; Craig Sable; Saate Shakil; Karen Sliwa-Hahnle; Benjamin Stark; Johan Sundström; Patrick Timpel; Imad M Tleyjeh; Marco Valgimigli; Theo Vos; Paul K Whelton; Magdi Yacoub; Liesl Zuhlke; Christopher Murray; Valentin Fuster Journal: J Am Coll Cardiol Date: 2020-12-22 Impact factor: 24.094